# Revenio Group Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/reveniogroup). ## Overview Revenio Group Oyj is a Finnish company specializing in comprehensive eye care diagnostic solutions. It operates internationally, providing fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration. The company's product portfolio includes iCare-branded tonometers, fundus imaging devices, perimeters, and software solutions. Revenio is listed on Nasdaq Helsinki and reported a revenue of €109.7 million in 2025. ## Products & services • iCare tonometers for eye pressure measurement • Fundus imaging devices for retinal diagnostics • Perimeters for visual field testing • Software solutions for eye diagnostics • Integrated diagnostic solutions for eye care - **Tonometers** (40%) — Devices for measuring eye pressure, primarily for glaucoma screening. - **Fundus Imaging Devices** (30%) — Equipment for capturing detailed images of the retina and optic nerve. - **Perimeters** (15%) — Instruments for assessing visual fields and detecting abnormalities. - **Software Solutions** (15%) — Diagnostic software for eye care professionals. - iCare tonometers for eye pressure measurement - Fundus imaging devices for retinal diagnostics - Perimeters for visual field testing - Software solutions for eye diagnostics - Integrated diagnostic solutions for eye care ## Customers Revenio's primary customers include ophthalmologists, optometrists, and eye care clinics worldwide. These professionals rely on Revenio's diagnostic tools for accurate and efficient eye disease screening and management. The company's products are also used in hospitals and research institutions for advanced eye health diagnostics. Additionally, Revenio serves the veterinary market with specialized tonometers for animal eye care. - **Ophthalmologists** (primary) — Purchase tonometers and imaging devices for glaucoma and retinal diagnostics. - **Optometrists** (secondary) — Use diagnostic tools for routine eye exams and disease management. - **Eye Care Clinics** (primary) — Implement integrated solutions for comprehensive patient care. - **Veterinary Professionals** (emerging) — Utilize specialized tonometers for animal eye health. - Ophthalmologists use tonometers for glaucoma screening. - Optometrists rely on fundus imaging devices for retinal diagnostics. - Eye care clinics utilize integrated solutions for comprehensive diagnostics. - Hospitals and research institutions use advanced diagnostic tools. - Veterinary professionals use tonometers for animal eye care. ## Geography Revenio operates globally, with a significant presence in the USA, which accounts for 48.3% of its revenue. The company also has a strong market in EMEA, LATAM, and Canada, contributing 33.7% of its revenue. The APAC region represents 16.4% of its sales, while Finland accounts for 1.6%. This diverse geographic footprint helps mitigate regional economic fluctuations and supports growth opportunities in emerging markets. - **USA** (48.3%) - **EMEA, LATAM, CAN** (33.7%) - **APAC** (16.4%) - **Finland** (1.6%) - USA is the largest market, contributing 48.3% of revenue. - EMEA, LATAM, and Canada together account for 33.7% of sales. - APAC region represents 16.4% of total revenue. - Finland contributes 1.6% to the overall sales. - Global presence supports growth and reduces regional risk exposure. ## Strategy Revenio's strategic priorities focus on enhancing clinical diagnostics through targeted product innovations and optimizing clinical pathways with integrated solutions. The company emphasizes customer-centric operations and sales, alongside continuous development of its workforce and culture. Revenio aims to sustain profitable growth by leveraging structural growth drivers in the eye care industry and maintaining high entry barriers for competitors. - **Product Innovation** (medium-term) — To improve diagnostic accuracy and efficiency. - **Integrated Solutions** (long-term) — To streamline clinical pathways and enhance patient care. - **Customer-Centric Operations** (short-term) — To enhance customer satisfaction and loyalty. - Enhancing clinical diagnostics with product innovations. - Optimizing clinical pathways through integrated solutions. - Strengthening customer-centric operations and sales. - Continuing workforce and culture development. - Sustaining profitable growth with high entry barriers. ## Risks Revenio faces several risks, including intense competition, technological advancements by competitors, and the need for successful commercialization of new technologies. The company is also exposed to geopolitical risks, particularly in regions like China, and operational risks related to supply chain disruptions. Additionally, currency fluctuations, especially between the euro and the dollar, can impact financial performance. Cybersecurity threats pose a risk to business continuity and reputation. - **Geopolitical risks** [high] — Exposure to unstable regions like China. - **Technological competition** [high] — Competitors' advancements could impact market position. - **Currency fluctuations** [medium] — Impact on revenue due to euro-dollar exchange rate changes. - **Cybersecurity threats** [critical] — Potential impact on operations and reputation. - Intense competition and technological advancements by competitors. - Geopolitical risks in key markets like China. - Supply chain disruptions affecting operations. - Currency fluctuations impacting financial performance. - Cybersecurity threats to business continuity and reputation. ## Accounting Revenio's financial statements are influenced by currency fluctuations, particularly between the euro and the dollar, which can significantly affect reported revenue. The company uses alternative performance measures to provide a clearer picture of its financial health, adjusting for currency impacts. Revenue recognition timing is crucial, as it affects quarterly performance comparisons. Additionally, the company must consider impairment of activated development expenses if commercialization projects fail. - **Currency Fluctuations** — high - **Revenue Recognition Timing** — medium - **Development Expense Impairment** — medium - Currency fluctuations impact reported revenue. - Alternative performance measures adjust for currency impacts. - Revenue recognition timing affects quarterly comparisons. - Impairment of development expenses if projects fail. --- *Last updated: 2026-08-11T04:04:55.521488+00:00*